PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33340714-12	2021	Response to lenvatinib in the cirrhotic PDX was associated with reduction in CD34, VEGFR2 and CLEC4G immunofluorescence area and intensity (all P<=0.03).	lenvatinib	12-22	kinase insert domain protein receptor	Mus musculus	83-89	
32722909-8	2020	Further, we show lenvatinib, a VEGFR2 tyrosine kinase inhibitor with a short half-life, to be superior to DC101, enhancing gemcitabine-induced endothelial cell apoptosis and tumor response in a multi-cycle treatment schedule.	lenvatinib	17-27	kinase insert domain protein receptor	Mus musculus	31-37	
31096155-6	2019	The binding conformations were respectively compared between VEGFR-2 with 13d and leading compound lenvatinib, and shows that they have similar binding modes.	lenvatinib	99-109	kinase insert domain protein receptor	Mus musculus	61-68	
32076044-5	2020	Lenvatinib, a multiple tyrosine kinase inhibitor including VEGFR and FGFR inhibition, showed marked antitumor activity against VEGFR2-Fc-expressing resistant tumors accompanied with a decrease in the area of tumor vessels and suppression of phospho-FGFR2 in tumors.	lenvatinib	0-10	kinase insert domain protein receptor	Mus musculus	127-133